The earnings call highlighted Allogene's strong financial position, expansion of clinical trials, and advancements in autoimmune therapies. However, there were challenges including safety concerns in the ALPHA3 trial and uncertainty regarding MRD conversion outcomes. Overall, the positive aspects slightly outweigh the concerns, suggesting cautious optimism.

Company Guidance

During Allogene Therapeutics' third quarter 2025 conference call, the company provided several key metrics and guidance. As of September 30, 2025, Allogene reported having $277.1 million in cash, cash equivalents, and investments, with a cash runway extending into the second half of 2027. Their R&D expenses for the third quarter were $31.2 million, including $2.8 million in noncash stock-based compensation, while G&A expenses were $13.7 million, including $5.9 million in noncash stock-based compensation. The net loss for the third quarter was $41.4 million or $0.19 per share, including $8.7 million in noncash stock-based compensation expense. The company anticipates a 2025 cash burn of approximately $150 million and full-year GAAP operating expenses of around $230 million, including an estimated $45 million in noncash stock-based compensation. Additionally, Allogene is focusing on pivotal interim data from their ALPHA3 trial and proof-of-concept data from ALLO-329 in autoimmune disease in the first half of 2026, which are expected to significantly impact the cell therapy landscape.

Strong Financial Position

As of September 30, 2025, Allogene had $277.1 million in cash, cash equivalents, and investments, supporting a cash runway into the second half of 2027.

Expanding Clinical Trials

The ALPHA3 trial has more than 50 active sites across the U.S. and Canada, with expansion into Australia and South Korea expected early next year.

Advancements in Autoimmune Therapy

ALLO-329 is a first-in-class allogeneic CD19, CD70 dual CAR T product designed for autoimmune diseases, with early proof-of-concept data expected in the first half of 2026.

Potential for Scalable Cell Therapy

Allogeneic technology offers a scalable backbone for potentially curative one-time off-the-shelf cell therapy, aiming to democratize access and reduce overall care costs.

Allogene Therapeutics (ALLO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALLO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	-0.22 / -	-0.28	―	―	―
Nov 06, 2025	2025 (Q3)	-0.22 / -0.19	-0.32	40.63% (+0.13)	―
Aug 13, 2025	2025 (Q2)	-0.27 / -0.23	-0.35	34.29% (+0.12)	―
May 13, 2025	2025 (Q1)	-0.29 / -0.28	-0.38	26.32% (+0.10)	―
Mar 13, 2025	2024 (Q4)	-0.33 / -0.28	-0.51	45.10% (+0.23)	―
Nov 07, 2024	2024 (Q3)	-0.33 / -0.32	-0.37	13.51% (+0.05)	―
Aug 07, 2024	2024 (Q2)	-0.35 / -0.35	-0.53	33.96% (+0.18)	―
May 13, 2024	2024 (Q1)	-0.41 / -0.38	-0.68	44.12% (+0.30)	―
Mar 14, 2024	2023 (Q4)	-0.45 / -0.51	-0.66	22.73% (+0.15)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.37	-0.58	36.21% (+0.21)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALLO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$1.05	$1.18	+12.38%
Aug 13, 2025	$1.04	$1.07	+2.88%
May 13, 2025	$1.13	$0.95	-15.93%
Mar 13, 2025	$1.89	$1.94	+2.65%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Allogene Therapeutics Inc (ALLO) report earnings?

Allogene Therapeutics Inc (ALLO) is schdueled to report earning on Mar 04, 2026, Before Open (Confirmed).

What is Allogene Therapeutics Inc (ALLO) earnings time?

Allogene Therapeutics Inc (ALLO) earnings time is at Mar 04, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALLO EPS forecast?

ALLO EPS forecast for the fiscal quarter 2025 (Q4) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing